IMMUNOGEN PEPTIDE AGAINST GROUP A STREPTOCOCCI Russian patent published in 2022 - IPC A61K39/02 A61K39/40 A61P31/04 C07K14/315 C07K4/04 C07K16/12 

FIELD: biotechnology.

SUBSTANCE: invention relates to biotechnology, namely to the use of isolated protein representing modified peptide p145 with a certain amino acid sequence, an antibody to this protein or isolated nucleic acid encoding this protein in the manufacture of a drug for: induction of an immune response of the mucous membrane to group A streptococcal bacteria in a mammal; induction of mucosal immunity against a streptococcal bacterial group A infection in mammals; or treatment or prevention of a streptococcal bacterial group A infection in a mammal, while isolated protein or its fragment or variant is capable of causing a response of the mucous membrane and/or inducing immunity of the mucous membrane to streptococcal bacterial group A infection in a mammal. A composition is presented, containing isolated protein, an antibody or an antibody fragment that binds or is produced against this protein; or isolated nucleic acid encoding isolated protein; and an immunogen fragment of SpyCEP protein, an antibody or an antibody fragment that binds or is produced against the immunogen fragment of SpyCEP, or isolated nucleic acid that encodes the immunogen fragment of SpyCEP, wherein the specified composition is intended for: induction of an immune response of the mucous membrane to group A streptococcal bacteria in a mammal; induction of mucosal immunity against streptococcal bacterial group A infection in a mammal; or treatment or prevention of streptococcal bacterial group A infection in a mammal, while isolated protein or its fragment or variant is capable of causing a response of the mucous membrane and/or inducing immunity of the mucous membrane to streptococcal bacterial group A infection in a mammal. Immunization with a single dose of modified peptide p145, rather than multiple immunizations, can protect against streptococcal group A infection, even of hypervirulent strains, such as the mutant CovR/S strain.

EFFECT: modified peptide, fragment or variant of p145 causes an immune response of the mucous membrane, when administered to a mammal, while IgA production is practically absent or is at a relatively low level compared to the level of produced IgG.

16 cl, 3 tbl, 22 dwg, 1 ex